医疗方面，京东方推出的X-ray平板探测器背板产品已广泛应用于欧美、日本、韩国等医疗器械公 司；智慧视窗通过显示和传感技术创新，为出行、建筑等领域提供传感器件及解决方案 ； 工业传 感器可应用于3C电子、半导体、物流、交通、新能源、医药与食品工业、汽车整车与零部件等行 业。 2024年，京东方传感业务的营收为3.86亿元，占公司总营收的0.19%。 具体来看，在 FPXD 领域，公司与 头部客户合作持续深化，销量同比提升；智慧视窗营收同比翻 倍增长，柔性LC智能光幕成功点亮，乘用车智能调光实现核心客户旗舰车型标配；苏州传感完成 光伏、锂电等行业多家头部客户导入；MEMS聚焦压力传感器领域推动产品化，并完成新场景多 产品拓展。 #京东方 #传感器 【WitsView整理】 爱企查显示，近日，北京京东方传感技术有限公司（下文简称北京京东方传 感）发生工商变更，注册资本由约47.86亿人民币增至约57.79亿人民币，增资近10亿元。北京京 东方传感作为京东方的全资子公司，主要负责其传感业务的运营。 图片来源：京东方 据介绍，京东方传感器及解决方案业务聚焦医疗生物、智慧视窗、工业传感器、消费电子等领域， 为客户提供专 ...

Group 1 - The core viewpoint of the news highlights the performance and market position of Yirui Technology, noting its current stock price, market capitalization, and PE ratio compared to industry averages [1] - As of March 31, 2025, Yirui Technology has 5,745 shareholders, a decrease of 883 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, and other core components, having mastered four major sensor technologies [1] Group 2 - In the latest quarterly report for Q1 2025, Yirui Technology achieved a revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, an increase of 2.74%, with a gross profit margin of 48.92% [1] - The company's rolling PE ratio is 38.27, which is lower than the industry average of 49.20 and the industry median of 36.56, ranking 77th in the industry [2] - The industry average PE ratio is 49.20, with a median of 36.56, indicating that Yirui Technology is positioned below the average in terms of valuation metrics [2]

证券分析师： 张钰莹 S0350524100004 zhangyy03@ghzq.com.cn [Table_Title] 主业筑底企稳，新技术百花齐放 ——奕瑞科技（688301）科创板公司动态研究 最近一年走势 | 相对沪深 | 表现 300 | | | 2025/04/30 | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 奕瑞科技 | | 6.1% | 18.8% | -13.9% | | 沪深 300 | | -3.7% | -1.2% | 4.6% | | 市场数据 | 2025/04/30 | | --- | --- | | 当前价格（元） | 121.01 | | 52 周价格区间（元） | 82.51-223.90 | | 总市值（百万） | 17,312.03 | | 流通市值（百万） | 17,312.03 | | 总股本（万股） | 14,306.28 | | 流通股本（万股） | 14,306.28 | | 日均成交额（百万） | 180.09 | | 近一月换手（%） | 0.00 | 2025 年 05 月 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][5]. Core Views - The company reported a revenue of 1.831 billion RMB in 2024, a decrease of 1.74% year-on-year, and a net profit of 465 million RMB, down 23.43% year-on-year. In Q1 2025, revenue was 482 million RMB, a decrease of 1.92%, while net profit increased by 2.74% to 143 million RMB [3][8]. - The company plans to distribute a cash dividend of 10.00 RMB for every 10 shares to all shareholders, reflecting its commitment to returning value to investors [3]. - Despite short-term performance pressures due to industry challenges, the company is viewed as a leader in the detector market, with a strong long-term growth potential [3][5]. Summary by Sections Financial Performance - The company’s revenue and net profit for 2024 were 1.831 billion RMB and 465 million RMB, respectively. The projected net profits for 2025-2027 are 680 million RMB, 743 million RMB, and 836 million RMB, with corresponding EPS of 4.75, 5.19, and 5.84 RMB [7][9]. - The company’s EBITDA for 2024 is projected at 472 million RMB, with a significant increase expected in subsequent years [7]. Market Position and Strategy - The company is focusing on increasing R&D investments, with 310 million RMB allocated in 2024, aimed at developing new products such as digital X-ray detectors and various types of industrial detectors [8]. - The company has completed its layout for comprehensive solutions, including key components like high-voltage generators and X-ray sources, with several products entering mass production in 2024 [8]. Valuation Metrics - The company’s projected P/E ratios for 2025, 2026, and 2027 are 25.8, 23.6, and 21.0, respectively, indicating a potential for valuation improvement as earnings grow [5][7]. - The projected dividend per share for 2025 is 1.5 RMB, with a dividend yield of 1.2% [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：688607 公司简称：康众医疗 第一节 重要提示 公司2024年年度利润分配方案为： 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、重大风险提示 公司已在本报告中详细阐述经营过程中可能存在的相关风险，敬请查阅"第三节 管理层讨论与分 析"之"四、风险因素"中有关风险的说明。 3、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4、公司全体董事出席董事会会议。 5、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 6、公司上市时未盈利且尚未实现盈利 □是 √否 7、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 1.2公司存托凭证简况 公司拟向全体股东每10股派发现金红利人民币0.61元（含税）。根据《上市公司股份回购规则》《上海 证券交易所上市公司自律监管指引第7号一一回购股份》等有关规定，上 ...

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...